TreeFrog Therapeutics introduces a game-changing technology for cell therapy manufacturing. Based on high-throughput cell encapsulation microfluidics, the C-Stem technology enables the mass-production and differentiation of pluripotent stem cells in 3D, within industrial bioreactors. Addressing critical market needs in terms of scalability, quality and operating costs, C-Stem is set to become a dominant design for cell therapy manufacturing, allowing millions of patients to access safe and affordable cell therapy products.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
iPS-derived cell therapy for Parkinson's disease
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):